Pradaxa, 110 mg capsules 180 pcs

PRADAXA – dabigatran etexilate is a low molecular weight prodrug that has no pharmacological activity. After oral administration, it is rapidly absorbed and is converted to dabigatran by esterase-catalyzed hydrolysis. Dabigatran is an active, competitive, reversible direct thrombin inhibitor and acts mainly in plasma.

Since thrombin (a serine protease) converts fibrinogen to fibrin during the coagulation cascade, inhibition of its activity prevents thrombus formation. Dabigatran inhibits free thrombin, fibrin-binding thrombin and thrombin-induced platelet aggregation.

In vivo and ex vivo animal studies using various models of thrombosis have demonstrated the antithrombotic efficacy and anticoagulant activity of dabigatran after intravenous administration and dabigatran etexilate after oral administration.

A close correlation between the concentration of dabigatran in plasma and the severity of anticoagulant effect was revealed. Dabigatran prolongs activated partial thromboplastin time (ATTB).

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

Special Instructions

Contraindications

Side effects

Hematopoietic and lymphatic system disorders: anemia, thrombocytopenia.

Immune system disorders: hypersensitivity reactions, including urticaria, rash and itching, bronchospasm.

Nervous system disorders: intracranial bleeding.

vascular disorders: hematoma, bleeding.

Respiratory, chest and mediastinal disorders: nasal bleeding, hemoptysis.

Gastrointestinal disorders: gastrointestinal bleeding, rectal bleeding, hemorrhoidal bleeding, abdominal pain, diarrhea, dyspepsia, nausea, ulceration of mucosa of the gastrointestinal tract, gastroesophagitis, gastroesophageal reflux disease, vomiting, dysphagia.

Hepatobiliary system disorders: increased “liver” transaminases activity, liver dysfunction, hyperbilirubinemia.

Skin and subcutaneous tissue changes: skin hemorrhagic syndrome.

Skeletal and muscular disorders, connective tissue and bone disorders: hemarthrosis.

Kidney and urinary tract changes: urogenital bleeding, hematuria.

General disorders and changes at the injection site: bleeding from the injection site, bleeding from the site of catheter insertion.

Damage, toxicity and complications from procedures: post-traumatic hematoma, bleeding from the site of surgical access.

Vascular disorders: bleeding from the surgical wound.

General disorders and disorders at the site of administration: bloody discharge.

Damage, toxicity and complications of postoperative treatment: hematoma after wound care, bleeding after wound care, anemia in the postoperative period, discharge from the wound after procedures, wound secretions.

Surgical and therapeutic procedures: wound drainage, drainage after wound care.

Overdose